Mining the full potential of GPCR signaling to innovate novel drugs
Conformation Driven Drug Discovery for G–Protein Coupled Receptors
Our proprietary membrane protein-NMR drug discovery platform identifies highly signaling-pathway selective molecules that bind to G-protein coupled receptor (GPCR) targets, eliminating on-target adverse effects that limit therapeutic index.
We know the value of innovative drug discovery and development…
MEBIAS’ business model is comprised of advancing and partnering Mebias’ wholly owned molecules into early clinical development. Seven years since its founding, the company has validated its unique drug discovery platform, identified an FDA-approved Investigational New Drug targeting the mu-opioid receptor, and is developing Sphingosine 1-phosphate receptor agonists for the treatment of neuropathic pain.
3675 Market Street Suite 200
Philadelphia, PA 19104